precision psychology

R&D

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

News

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.